В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб...ркулеза, в том числе новым и применяющимся по новым показаниям.
more
The 2018 Access to Medicine Index finds that the pharmaceutical industry continues to mature in its approach to access to medicine, with models for good practice in areas such as access planning and licensing. GSK retains its No. 1 position, as Novartis moves up into 2nd. Takeda rises furthest in 20...18, jumping ten places to fifth
Download the full report from (Large File 22 MB)
https://accesstomedicinefoundation.org/media/uploads/downloads/5c8bc9ceb714b_Access%20to%20Medicine%20Index%202018.pdf
more
Introdução
Capítulo A.9
Edição em Português
Editor: Flávio Dias Silva.
Tradutores: Letícia Tomaz Oliveira, Luciano da Silva Quadros
Introductión
Capítulo A.9
Edición: Matías Irarrázaval & Andres Martin
Traducción: Fernanda Prieto-Tagle & José Montejo
Guidelines for Primary, Secondary and Tertiary Level Care
A new formulation of a drug to prevent excessive bleeding following childbirth could save thousands of women’s lives in low- and lower-middle-income countries, according to a study led by the World Health Organization (WHO) in collaboration with MSD for Mothers and Ferring Pharmaceuticals.
Curren...tly WHO recommends oxytocin as the first-choice drug for preventing excessive bleeding after childbirth. Oxytocin, however, must be stored and transported at 2–8 degrees Celsius, which is hard to do, in many countries, depriving many women of access to this lifesaving drug. When they can obtain it, the drug may be less effective because of heat exposure.
more
Anxiety disorders
Chapter F.3
Trastornos externalizantes
Capítulo D.1
Edición: Matías Irarrázaval & Andrés Martín
Traducción: Fernanda Prieto Tagle, Marta García Acuña
Trastornos de ansiedad
Capítulo F.3
Editores: Laura Revert, Matías Irarrázaval & Andres Martin
Traducción: Régis Villegas, Paula Placencia, José Ángel Alda & Paula Cox
Troubles Anxieux
Chapitre F.3
Edition en français
Traduction : Alexis Revet
Sous la direction de : Jean-Philippe Raynaud Avec le soutien de la SFPEADA
(15 April 2020, BST 17:00 hours)
Actions Taken from Bangladesh Red Crescent Society (BDRCS):
9292 Number of staff and RCY/ CPP/ Camp/ Community volunteers being mobilized throughout the country.
10116 Set of PPE provided to individuals working on COVID-19 response.
130,851 Number of Total Peop...le Reached (average/day)
313 Religious /Community Leaders reached through Hygiene promotion initiatives.
1,000,000+ People received life-saving awareness messages through social media.
786,000 People reached through Information, Education and Communication (IEC) materials across the country.
10179 Hand-washing station established throughout the country including camp settlements in Cox’s Bazar.
166601 Hygiene and Protecting gears distributed i.e Soap (91686), Hand sanitizer(36650), Mask (33445), Hand Gloves (1908), Eye Protector (2912).
2005 Hospitals/ Institutions/ places already covered through disinfectant spraying.
12181 Women reached through Dignity Kit Distribution
more
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is presented in a brochure that is now available in English...
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.2 This Pharma-Brief Special presents the results. It examines the risks for humans, animals and the environment. It focuses on local problems and approaches, international interactions and the re-sponsibility of doctors, farmers and consumers.
more
Injection practices worldwide and especially in low- and middle-income countries (LMICs) include multiple, avoidable unsafe practices that ultimately lead to the large-scale transmission of bloodborne viruses among patients, health care providers and the community at large.
Chagas disease affects approximately 6 million people, mainly in Latin America. Less than 1% of affected individuals receive proper antiparasitic treatment, and current drugs are inadequate to fight the entire spectrum of the disease. Against this background, Novartis is pursuing an end-to-end appro...ach, with activity on three fronts: drug discovery, clinical research and health system strengthening.
more
WHO promotes the inclusion of foodborne trematodiases among the targets of preventive chemotherapy interventions. With the aim of providing access to quality medicines, WHO has negotiated with Novartis Pharma AG whereby Novartis donates triclabendazole for the treatment of fascioliasis and paragonim...iasis in endemic countries. WHO collects applications from ministries of health and medicines are shipped free of charge.
more